These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20803611)

  • 1. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.
    Vranic S; Teruya B; Repertinger S; Ulmer P; Hagenkord J; Gatalica Z
    Cancer; 2011 Jan; 117(1):48-53. PubMed ID: 20803611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS; Wang Y; Tull J; Zhang S
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
    Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z
    Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 genetic heterogeneity in breast carcinoma.
    Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
    J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
    Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
    J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
    Orsaria M; Khelifa S; Buza N; Kamath A; Hui P
    J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment and significance of human epidermal growth factor receptor 2 gene status in breast cancer with polysomy of chromosome 17].
    Zhang H; Si JW; Zhang S; Wang Y; Li D; Li T
    Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):124-9. PubMed ID: 26899332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
    Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
    Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.